New clinical evidence: We’re pleased to confirm that the AUSSIE study has been published in BJU International. AUSSIE – the second peer reviewed clinical validation of Triage Plus and the first in an Australian population – reproduces the performance seen in the recent DRIVE study and gives Australian clinicians and hospitals local peer-reviewed evidence supporting use of the test to help rule out urothelial cancer and defer an invasive cystoscopy and unnecessary imaging in patients with a low probability of disease. For clinical teams outside Australia, AUSSIE provides important new evidence that Cxbladder Triage Plus performs consistently across different patient populations and health systems. Learn more: hubs.la/Q04CqJpQ0

News to share! Pacific Edge today releases its Q2 27 Investor Update, reporting increased momentum towards its US commercial recovery. Learn more and review the update: hubs.la/Q04BvyNB0

#InvestorWebinar Last week Pacific Edge CEO Dr Peter Meintjes participated in the first of MST Financials' four-part Biotech & Healthcare Webinar Series. Focused on diagnostics, the session provided investors with an overview of Pacific Edge's first-mover advantage and leadership position in bladder cancer diagnostics, recent Medicare coverage and pricing milestones, and the expanding market opportunity for Cxbladder. During the discussion, Dr Meintjes outlined Pacific Edge's growth strategy, including ongoing clinical evidence generation, expanded reimbursement coverage, increased commercial adoption and key initiatives to support long-term scalability. Pacific Edge CFO Grant Gibson then concluded the presentation with a strategic update on the company's financial performance and path to profitability. MST Biotech & Healthcare Webinar 1: Diagnostics | View the video: hubs.la/Q04zS2Nm0

A thought-provoking conversation with AUA President and Kaiser Permanente Chair of Urology Dr Eugene Rhee on the future of urology and the role of the AUA in advancing innovation, education and collaboration across the specialty. As new diagnostic technologies and precision medicine approaches continue to emerge, evidence-based guidance is critical to informed clinical decision-making and improved patient outcomes. We appreciate the AUA's leadership across urology to help ensure innovation translates to meaningful benefits for patients.

Upcoming event! From Sunday, we'll be at the Annual Meeting of the American Urogynecologic Society (AUGS). Tying in to this year's theme - Innovations and Practice-Changing Science, and a meeting focus on forward-thinking research and clinical excellence, we're looking forward to discussing Triage Plus, our next generation Cxbladder genomic test for the risk stratification of patients presenting with microhematuria. To learn more, we invite you to join us at the Cxbladder booth. With the publication of LCD DL40378, Triage Plus is expected to be covered by Medicare in appropriately counseled intermediate risk patients.  #NonInvasive #UCRiskStratification

Upcoming webinar! Pacific Edge CEO Dr Peter Meintjes will be participating in the first of MST's four part Biotech & Healthcare Webinar Series, designed to showcase innovative ASX-listed companies working at the forefront of healthcare and biotechnology. Webinar 1: Diagnostics | Tuesday, October 6, 4pm AEDT Register now: hubs.la/Q04yRMTl0

A reminder for all those seeking an internship - applications for our 2026-27 Summer Internship Programme are now open through till 7 Oct. This year we're looking to fill four positions to work across four different projects in support of our clinical trials programme. To learn more about the available roles, projects, eligibility criteria and how to apply, visit our Careers Hub at hubs.la/Q04yw7S10. You’ll also find Q&As with former interns who have transitioned into commercial roles as they share their firsthand experiences and advice for applicants. #Internships #ClinicalResearch

Expert Webinar - Cxbladder Triage Plus for Microhematuria Evaluation: hubs.la/Q04y93MW0 Pacific Edge Chief Medical Officer Dr Tamer Aboushwareb provides an overview, discussing: - Nuances in hematuria evaluation and the impact of recent AUA/SUFU Microhematuria Guideline changes - The advantages of urine-based genomic testing supported with real world evidence - The development and clinical validation of Triage Plus, including active studies - Practical considerations in the use of Triage Plus Watch the video: hubs.la/Q04y93MW0 US clinicians: With the publication of LCD DL40378, Triage Plus is expected to be covered by Medicare for the evaluation of appropriately counseled intermediate risk microhematuria patients.

A reminder for all those planning to attend or follow the event online - Pacific Edge CEO Dr Peter Meintjes will be presenting at the ASX SMIDcaps Conference today at 2:25pm AEST (4:45pm NZT), at the Library Auditorium, State Library of NSW, Sydney. If you haven't ready, you can register via this link: hubs.la/Q04y54VW0 #ASXSMIDcaps

Upcoming event! Pacific Edge CEO Dr Peter Meintjes will be presenting at the upcoming ASX SMIDcaps Conference on Wednesday 23 September, 2:25pm AEST, at the Library Auditorium, State Library of NSW, Sydney. Join us in person or online via the live stream. Dr Meintjes will share an update on Pacific Edge's strategy, latest achievements and vision for the future. Register now: hubs.la/Q04xQffq0 #ASXSMIDcaps

A reminder for all those seeking internship opportunities! Chiasma's Synapse event is being held in the University of Otago Union tonight from 6pm. It's a key event for STEM students and grads who are looking to make the move to a commercial role and we'll be running a booth to promote our 2026-27 Summer Internships. This year we have 4 positions available to work across four projects in support of our Clinical Trials Programme. Applications are now open through to 7 October. To learn more, we invite you to come and join us tonight from 6pm. You can also find more information on our Careers Hub at: hubs.la/Q04xCMF90

An important update for all those seeking an internship! Applications for our 2026-27 Summer Internship Programme are now open. This year we're seeking four interns to work across four different projects in support of our clinical trials programme. To learn more, we invite you to join us at Chiasma's Synapse event this Wednesday, 16 September, 6-9 pm in the Union Hall. We'll be running a booth and happy to answer your questions.  You can also find more information on our Careers hub at hubs.la/Q04xl2Ps0 including Q&A's with previous interns who have now made the transition to commercial roles. #Internships #ClinicalResearch

News to share! Pacific Edge is pleased to announce the appointment of Willy Iglesias as Chief Digital Officer, a role central to the company’s strategy to extend its first mover advantage in bladder cancer diagnostics. Learn more: hubs.la/Q04tXNlj0

New vacancy! We're looking for an experienced Clinical Trials Associate to be based at the Centre for Innovation in Dunedin. This is an exciting time for the business and you'll play an important role supporting our clinical evidence generation programme — a programme that has already seen our tests included in leading clinical guidelines recognised around the world. If you're passionate about advancing cancer diagnostics and want to play a key role in our next chapter, learn more and apply here: hubs.la/Q04swf850 #HealthJobsNZ #ClinicalResearch

British comedian Alan Davies kicks off his New Zealand tour today and we'd like to thank his team and participating venues throughout New Zealand for letting us promote an important symptoms awareness message as guests take a break during the show. As we like to say, some things should be red, not your pee. If you see red, speak to your GP. If you haven't already, make sure you read Alan's article in Stuff Magazine: hubs.la/Q04rqRdL0. We also encourage you to support Alan on tour: hubs.la/Q04rrrDT0 A big thank you to all the venues that have pledged their support thus far: BNZ Theatre Hamilton, Addison Theatre Tauranga, Napier Municipal Theatre, Michael Fowler Centre Wellington, and the Regent Theatre Dunedin.

Q1 27 Investor Update: Pacific Edge today announces its APAC business is advancing towards profitability on a direct-cost basis supported by an increase in commercial test volumes and the increasing adoption of the company’s next generation test Cxbladder Triage Plus. Learn more and review the update: hubs.la/Q04pnv_10

An update for shareholders and investors: Pacific Edge is pleased to present its Annual Report for the year ended 31st March 2026. Review the Annual Report: hubs.la/Q04mBKZF0

A reminder why it's so important to recognise the symptoms: hubs.la/Q04mpwT20 Blood in urine is the most common symptom of bladder cancer and often the first sign. If you see red in your pee, speak to your GP. The disease is highly treatable when caught early. We're fans and wish Alan well. See you in Dunedin on the 13th August!

#WatchNow. Late last year we hosted an expert panel discussion focused on the utility of Cxbladder Triage in the evaluation of patients with microhematuria. In this mini-clip, taken from the 50min session, Dr. Jhaveri and Dr. Goldfischer discuss the use of Cxbladder to help optimize practice workflow, prioritizing those who require care: hubs.la/Q04lNh580 View the full webinar: hubs.la/Q04lNm9v0 == Cxbladder Triage is a non-invasive genomic urine test optimized to risk stratify and rule out urothelial cancer in patients presenting with microhematuria. The test is included in the AUA/ SUFU Microhematuria Guideline, supported with Grade A evidence, and US Medicare coverage for the use of Triage and Triage Plus in appropriately counseled intermediate risk patients has been proposed with the recent publication of a draft LCD. Learn more: hubs.la/Q04lNq-30

News to share! Pacific Edge Completes NZ$36.1 Million Capital Raising; Retail Offer Closes Significantly Oversubscribed. Learn more: hubs.la/Q04jS2Sl0